Literature DB >> 33060063

Triple Artemisinin-Based Combination Therapies for Malaria - A New Paradigm?

Rob W van der Pluijm1, Chanaki Amaratunga1, Mehul Dhorda2, Arjen M Dondorp3.   

Abstract

Recent gains in the fight against malaria are threatened by the emergence and spread of artemisinin and partner drug resistance in Plasmodium falciparum in the Greater Mekong Subregion (GMS). When artemisinins are combined with a single partner drug, all recommended artemisinin-based combination therapies have shown reduced efficacy in some countries in the GMS at some point. Novel drugs are not available for the near future. Triple artemisinin-based combination therapies, combining artemisinins with two currently available partner drugs, will provide one of the last remaining safe and effective treatments for falciparum malaria that can be deployed rapidly in the GMS, whereas their deployment beyond the GMS could delay or prevent the global emergence and spread of resistance to currently available drugs.
Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  ACT; P. falciparum; TACT; artemisinin; malaria; resistance

Mesh：

Substances：

Year:  2020        PMID： 33060063     DOI： 10.1016/j.pt.2020.09.011

Source DB:  PubMed          Journal:  Trends Parasitol        ISSN： 1471-4922


  18 in total

1.  Is triple artemisinin-based combination therapy necessary for uncomplicated malaria?

Authors:  Rob W van der Pluijm; Thomas J Peto; Mainga Hamaluba; James J Callery; Rupam Tripura; Nicholas J White; Arjen M Dondorp
Journal:  Lancet Infect Dis       Date:  2022-06       Impact factor: 71.421

2.  New Acyl Derivatives of 3-Aminofurazanes and Their Antiplasmodial Activities.

Authors:  Theresa Hermann; Patrick Hochegger; Johanna Dolensky; Werner Seebacher; Robert Saf; Marcel Kaiser; Pascal Mäser; Robert Weis
Journal:  Pharmaceuticals (Basel)       Date:  2021-04-27

Review 3.  Canonical transient receptor potential channels and their modulators: biology, pharmacology and therapeutic potentials.

Authors:  Yuan-Yuan Gao; Wen Tian; Hui-Nan Zhang; Yang Sun; Jing-Ru Meng; Wei Cao; Xiao-Qiang Li
Journal:  Arch Pharm Res       Date:  2021-03-24       Impact factor: 4.946

4.  Market Formation in a Global Health Transition.

Authors:  Freek de Haan; Ellen H M Moors; Arjen M Dondorp; Wouter P C Boon
Journal:  Environ Innov Soc Transit       Date:  2021-09       Impact factor: 9.680

5.  To what extent are the antimalarial markets in African countries ready for a transition to triple artemisinin-based combination therapies?

Authors:  Freek de Haan; Oladimeji Akeem Bolarinwa; Rosemonde Guissou; Fatoumata Tou; Paulina Tindana; Wouter P C Boon; Ellen H M Moors; Phaik Yeong Cheah; Mehul Dhorda; Arjen M Dondorp; Jean Bosco Ouedraogo; Olugbenga A Mokuolu; Chanaki Amaratunga
Journal:  PLoS One       Date:  2021-08-31       Impact factor: 3.240

6.  Evolution of Multidrug Resistance in Plasmodium falciparum: a Longitudinal Study of Genetic Resistance Markers in the Greater Mekong Subregion.

Authors:  Mallika Imwong; Kanokon Suwannasin; Suttipat Srisutham; Ranitha Vongpromek; Cholrawee Promnarate; Aungkana Saejeng; Aung Pyae Phyo; Stephane Proux; Tiengkham Pongvongsa; Nguon Chea; Olivo Miotto; Rupam Tripura; Chau Nguyen Hoang; Lek Dysoley; Nghia Ho Dang Trung; Thomas J Peto; James J Callery; Rob W van der Pluijm; Chanaki Amaratunga; Mavuto Mukaka; Lorenz von Seidlein; Mayfong Mayxay; Nguyen Thanh Thuy-Nhien; Paul N Newton; Nicholas P J Day; Elizabeth A Ashley; Francois H Nosten; Frank M Smithuis; Mehul Dhorda; Nicholas J White; Arjen M Dondorp
Journal:  Antimicrob Agents Chemother       Date:  2021-09-13       Impact factor: 5.191

7.  Challenges in the clinical development pathway for triple and multiple drug combinations in the treatment of uncomplicated falciparum malaria.

Authors:  Quique Bassat; Oumou Maïga-Ascofaré; Jürgen May; Jerôme Clain; Ghyslain Mombo-Ngoma; Mirjam Groger; Ayôla A Adegnika; Jean-Claude Dejon Agobé; Abdoulaye Djimde; Johannes Mischlinger; Michael Ramharter
Journal:  Malar J       Date:  2022-02-22       Impact factor: 2.979

8.  Triple therapy with artemether-lumefantrine plus amodiaquine versus artemether-lumefantrine alone for artemisinin-resistant, uncomplicated falciparum malaria: an open-label, randomised, multicentre trial.

Authors:  Thomas J Peto; Rupam Tripura; James J Callery; Dysoley Lek; Ho Dang Trung Nghia; Chea Nguon; Nguyen Thi Huyen Thuong; Rob W van der Pluijm; Nguyen Thi Phuong Dung; Meas Sokha; Vo Van Luong; Le Thanh Long; Yok Sovann; Jureeporn Duanguppama; Naomi Waithira; Richard M Hoglund; Palang Chotsiri; Nguyen Hoang Chau; Andrea Ruecker; Chanaki Amaratunga; Mehul Dhorda; Olivo Miotto; Richard J Maude; Huy Rekol; Kesinee Chotivanich; Joel Tarning; Lorenz von Seidlein; Mallika Imwong; Mavuto Mukaka; Nicholas P J Day; Tran Tinh Hien; Nicholas J White; Arjen M Dondorp
Journal:  Lancet Infect Dis       Date:  2022-03-08       Impact factor: 71.421

Review 9.  Review of the Current Landscape of the Potential of Nanotechnology for Future Malaria Diagnosis, Treatment, and Vaccination Strategies.

Authors:  Arnau Guasch-Girbau; Xavier Fernàndez-Busquets
Journal:  Pharmaceutics       Date:  2021-12-17       Impact factor: 6.321

Review 10.  Artemisinin and multidrug-resistant Plasmodium falciparum - a threat for malaria control and elimination.

Authors:  Mehul Dhorda; Chanaki Amaratunga; Arjen M Dondorp
Journal:  Curr Opin Infect Dis       Date:  2021-10-01       Impact factor: 4.915
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.